Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Ltd., an Australian pharmaceutical company specializing in Focal Adhesion Kinase inhibitors for cancer and fibrosis, has announced a change in the director’s interest. Dr. Christopher Burns has acquired 347,826 ordinary shares and 260,869 listed options in the company. This move highlights ongoing developments in Amplia’s strategic focus on targeting fibrotic cancers and chronic diseases.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.